Stay updated on IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial
Sign up to get notified when there's something new on the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page.

Latest updates to the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page
- ChecktodayChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed; no other substantive changes were made.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%
- Check15 days agoChange DetectedThe web page has been updated to include specific drug information related to Odevixibat and its availability for treating primary biliary cholangitis, along with a new facility name and location in Gothenburg, Sweden. However, several previous location-related terms and topics have been removed.SummaryDifference5%
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference2%
Stay in the know with updates to IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page.